SEPN: Septerna, Inc.
Performance
SEPN +174.12%
Watchlist
Select an item
Summary
SEPN at a glance
SEPN returned +174.12% over the past year. Its worst drop in that year was -25.98%, smaller than 67% of stocks on Redstone, and its Sharpe ratio of 1.77 beats 96% of stocks on Redstone. It pays no dividends.
Current Drawdown
0.00%
Rolling Volatility
55.52%
Actions
Metrics
Risk Indicators
Alpha109.64%
Beta1.01x
Sharpe1.77
Sortino3.37
Omega1.36
Calmar6.70
Martin8.47
Profile
About SEPN
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $2.4B
- Listed
- Oct 2024
- Employees
- 130
- Headquarters
- South San Francisco, CA
- Website
- septerna.com
Comparisons